| Development update
EloraTZP is a combination of two medicines, eloralintide and tirzepatide, that Eli Lilly is testing for weight loss. AMPLIFY-2 is its phase 3 trial in adults with obesity or overweight and type 2 diabetes. ClinicalTrials.gov now lists the trial as recruiting, with a start date of October 16, 2026 that the registry marks as actual.
The registry lists 1,000 planned participants. One group receives EloraTZP and the other receives tirzepatide alone, both by injection under the skin. The main goal is the percent change in body weight from the start of the trial to week 100, and the estimated primary completion date is October 2029. Of the 75 listed sites, one (Los Angeles Institute for Metabolic Research) is marked recruiting. The other 74 are marked not yet recruiting.
The companion trial, AMPLIFY-1 (NCT07881432), tests the combination in adults with obesity without type 2 diabetes. It plans 2,115 participants and is still listed as not yet recruiting, with an estimated start in December 2026.
On its October 29 earnings call, Lilly said the phase 3 trials of the co-formulated EloraTZP will use a slower, optimized dose escalation schedule, which it expects to improve tolerability, and that it looked forward to starting them imminently. The registry gives the route but lists no dose amounts, no dosing frequency and no escalation schedule for either group.
Worth knowing: This is a status change on a registry, not a result. No AMPLIFY-2 data exist, and one open site does not mean the whole trial is enrolling. Because no dose amounts or schedule are listed, the registry shows nothing about how much of either medicine people receive. The statements from the earnings call are company-reported and come from a third-party transcript copy. Eloralintide and EloraTZP are investigational and not approved anywhere.
Follow eloralintide on the tracker. The first Phase 3 completion in the trial registry is Jan 2028. Every dated trial completion, filing and FDA decision for eloralintide is on the pipeline tracker, each with its source.
Related: Eloralintide medicine page | Lilly tracker | Drug pipeline
Source: ClinicalTrials.gov, AMPLIFY-2 (NCT07881458) Trial registry. Eli Lilly and Company, third-quarter 2026 earnings call, October 29, 2026, third-party transcript copy Company statement.